Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our Life Science HR Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Close
Susan T. Hubbard is Executive Vice President of Public Affairs and Investor Relations at Exelixis. In this role since December 2016, Ms. Hubbard is responsible for developing the company’s global corporate brand marketing and communications strategy to build Exelixis’ reputation among diverse corporate audiences. Ms. Hubbard led the company’s 2017 rebrand to codify its mission, culture and core values and built out Exelixis’ corporate communications function with a team whose charter includes bringing to life the significant contributions the company has made to the treatment of cancer. Ms. Hubbard oversees all aspects of the company’s corporate, partnership and product communications, as well as employee, investor and advocacy relations to reinforce Exelixis’ unrelenting commitment to the field of oncology and bold vision for the future. A public relations and investor relations consultant to Exelixis since 2014, Ms. Hubbard was instrumental in developing Exelixis’ communications strategy around the launch of CABOMETYX, as well as managing the announcements of several other major milestones for its partnered programs. Previously, Ms. Hubbard spent over two decades at
Gilead Sciences, Inc., where she occupied a variety of roles of increasing responsibility, concluding her tenure as Vice President of Investor Relations. Ms. Hubbard holds a B.A. in Psychology from the University of California, Los Angeles.